NASDAQ:AKCA - Akcea Therapeutics Stock Price, Forecast & News

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Akcea Therapeutics Inc (NASDAQ:AKCA) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.21. The firm earned $20.62 million during the quarter, compared to analysts' expectations of $22.54 million. Akcea Therapeutics had a negative net margin of 50.71% and a negative return on equity of 33.00%. The company's revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.73) EPS. View Akcea Therapeutics' Earnings History.

Akcea Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Akcea Therapeutics.

4 analysts have issued 12 month price targets for Akcea Therapeutics' stock. Their forecasts range from $24.00 to $41.00. On average, they anticipate Akcea Therapeutics' share price to reach $34.67 in the next year. This suggests a possible upside of 90.0% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.

Headlines about AKCA stock have been trending somewhat negative on Monday, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Akcea Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Akcea Therapeutics.

Some companies that are related to Akcea Therapeutics include The Medicines (MDCO), Horizon Therapeutics (HZNP), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH) and SAGE Therapeutics (SAGE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH).

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKCA stock can currently be purchased for approximately $18.25.

Akcea Therapeutics has a market capitalization of $1.71 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.View Additional Information About Akcea Therapeutics.

The official website for Akcea Therapeutics is http://www.akceatx.com/.

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]